To the Editor: Varied dosing regimens of rituximab (RTX) have been successfully used in the management of primary membranous nephropathy (PMN).
1,2 An ideal RTX dose and the long-term adverse effect of a larger cumulative dose are not clear. CD19 levels are used to gauge the drug effect. 1 Economic viability is a major part of any new therapeutic regimen. Low-dose RTX (100 mg) has been successfully used in ABO incompatible renal transplant. 3 In the present study, we report a similar approach of CD19 depletion using 100 mg of RTX in the management of M-type phospholipase A2 receptor antibody (aPLA 2 R)-associated PMN refractory, dependent on or intolerant to conventional immunosuppressive regimens recommended by Kidney Disease: Improving Global Outcomes. 4 All the study subjects had aPLA 2 R-related PMN. The mean duration of nephrotic syndrome before RTX therapy was 33.67 AE 19.76 (median 13, range 10-62) months. Before receiving RTX, all the patients had an immunosuppression-free washout period of minimum 3 months. The mean proteinuria, serum albumin, and creatinine were 12.06 AE 10.78 (median 7.59, range 2.30-31.00) g/d, 2.09 AE 0.95 (median 1.64, range 1.30-3.50) g/dl, and 0.81 AE 0.21 (median 0.80, range 0.60-1.10) mg/dl, respectively. Five (83.3%) study subjects had nephrotic range proteinuria (>4 g/d) and 1 (16.7%) patient had subnephrotic proteinuria (2.3 g/d) and was treated as he had anasarca with severe hypoalbuminemia (1.3 g/dl) and hypercholesteremia. All the study subjects (4 resistant to cyclophosphamide and steroids, 1 intolerant to tacrolimus treatment, and 1 with relapsing disease) were treated with 100 mg of rituximab (CD19 monitored on day 2 and at every 4-to 6-week interval). In subjects with no response at 6 months, further infusion and monitoring was stopped (extended follow-up continued). All the subjects achieved CD19 depletion (<1%) with a single dose of 100 mg of RTX. All the patients received maximal tolerable doses of angiotensin receptor blockers (systolic blood pressure achieved was <130 mm Hg in all the subjects) and atorvastatin; doses of angiotensin receptor blockers were stable during the entire study period. During RTX therapy, the patients received no other immunosuppressive therapy. At the end of 6 months, 3 (50%) achieved remission in proteinuria with normalization of serum albumin, and had maintained it until the last follow-up (Table 1 ). All the subjects in clinical remission also had serological remission and nonresponders had persisting aPLA 2 R ( Table 1 ). The mean time for CD19 reconstitution was 2.17 AE 1.17 (median 2, range 1-4) months. A total of 16 additional doses of RTX were required (mean 2.67 AE 0.82, median 2.5, and range 2-4).
Low-dose RTX has been successfully used in ABO incompatible renal transplant. Nakao et al. 3 reported successful use of 100 mg of RTX in 9 ABO incompatible renal transplant, with no difference in survival rates between low versus standard dose. Low dose of RTX has also been successfully evaluated in refractory rheumatoid arthritis. 5 Shenoy et al. 5 evaluated the therapeutic response of 100 mg of RTX in 14 patients with active rheumatoid arthritis; 58% and 42% of the patients achieved good and moderate response at 24 weeks, respectively. Seventy-nine percent of the patients achieved CD19 depletion (<0.01%) with single dose of RTX (100 mg). The CD19 depletion in the present study is better than that reported by Shenoy et al.; this may partly be explained by the difference in the definition of CD19 depletion (<1% and <5 cells in the present study vs. <0.01% in the study by Shenoy et al.). 5 Ruggenenti et al.
1 studied RTX use in 100 subjects with PMN and reported a response rate of 56% (18 of 32 cases), when used as a second line agent. In the present study, the response rate of 50% was similar to that reported by Ruggenenti et al. 1 Ruggenenti et al. used a single dose of 375 mg/m 2 in all the patients compared with 100 mg with CD19 monitoring in the present study. Treatment protocol utilizing RTX in PMN widely varies among various centers; some prefer to use "extended protocol" of weekly (375 mg/m 2 ) RTX for 4 weeks, 6 whereas others choose to use CD19 targeted RTX infusion. Interestingly, most of the studies have demonstrated successful depletion of CD19 with a single dose, questioning the benefit of additional dosing, and many centers have evolved from "extended protocol" to "CD19 targeted dosing." 1, 6 Assuming that CD19 depletion primarily translates to clinical response, any dose that achieves it must be acceptable. aPLA 2 R has very good association with clinical activity; 7 in the present report, all the responders had reduction in aPLA 2 R to <20 RU/ml, whereas none of the nonresponders achieved similar titer. Our results support the incorporation of aPLA 2 R monitoring in the management of difficult to treat PMN.
To conclude, in cost-restrained setting, low-dose RTX targeting CD19 depletion can be used in the management of PMN refractory to standard immunosuppressive therapies with the acceptable side effect profile. To the Editor: Serum albumin is a useful screening tool for recognizing protein energy wasting (PEW) in dialysis patients. However, there are many nonnutritional conditions that are far more important determinants of serum albumin levels than a patient's nutritional state.
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1,2 Nevertheless, we have observed that it is not unusual for caregivers to make a reflex connection between serum albumin and dietary protein intake and to act on an unfounded belief that protein 
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